GGTUAGDM: GGT and Uric Acid to Predict Gestational Diabetes Mellitus

Sponsor
Mount Carmel Health System (Other)
Overall Status
Recruiting
CT.gov ID
NCT04956094
Collaborator
Mount Carmel Foundation (Other)
200
1
30.3
6.6

Study Details

Study Description

Brief Summary

Gestational Diabetes Mellitus (GDM) is a common metabolic complication of pregnancy defined as new onset hyperglycemia during gestation. GDM conveys significant risk of morbidity and mortality for both mother and infant. An estimated 268,900 infants were born to mothers with GDM in the USA, accounting for approximately 6.9% of births. Although individual correlations have been found between elevated GGT and uric acid levels and later development of GDM, no research has established and validated combined criteria for GGT and uric acid levels that would lead to their use in identifying women at high risk of GDM in the first trimester.

Central Hypothesis: Serum GGT and serum uric acid collected between >9-14.0 weeks gestation will be significantly elevated in women who later develop GDM compared to those who do not. Combined analysis of serum uric acid and GGT levels within the first trimester allows for accurate prediction of the development of GDM.

Study population includes women between 9-14 weeks gestation undergoing a standard first trimester blood draw. Additional blood will be drawn during the standard blood draw to assess GGT and uric acid levels. Research participants will be tracked afterwards to determine whether they tested positive for gestational diabetes during the standard testing process which typically occurs at 24-28 weeks gestation. The data will then be analyzed to estimate the sensitivity, specificity, positive and negative predictive values of the first trimester GGT and uric acid tests. The GGT and uric acid levels which maximize the area under the receiver-operator characteristic curve will be identified.

Condition or Disease Intervention/Treatment Phase
  • Diagnostic Test: GGT/Uric Acid

Study Design

Study Type:
Observational
Anticipated Enrollment :
200 participants
Observational Model:
Cohort
Time Perspective:
Prospective
Official Title:
Association of Elevated Serum Gamma Glutamyl Transferase (GGT) and Uric Acid at 9-14 Weeks Gestation With the Development of Gestational Diabetes Mellitus (GDM)
Actual Study Start Date :
Jun 21, 2021
Anticipated Primary Completion Date :
Jun 30, 2023
Anticipated Study Completion Date :
Dec 31, 2023

Arms and Interventions

Arm Intervention/Treatment
First Trimester Prenatal Visit

Women attending an initial first trimester prenatal visit who will be undergoing a standard blood draw.

Diagnostic Test: GGT/Uric Acid
Standard laboratory blood testing for GGT and uric acid levels.

Outcome Measures

Primary Outcome Measures

  1. Proportion of patients diagnosed with gestational diabetes mellitus [24-28 weeks]

    Diagnosis of gestational diabetes mellitus (GDM) via oral glucose tolerance testing (Carpenter and Coustan criteria)

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years and Older
Sexes Eligible for Study:
Female
Inclusion Criteria:
  • Pregnant women between > 9 weeks and < 14.0 weeks gestation
Exclusion Criteria:
  • Known history of or current diagnosis of type I or type II diabetes mellitus

  • Known liver disease

  • Known kidney disease

  • Known history of or current diagnosis of gout

  • Known history of alcoholism or current alcohol use

  • Multiple gestation

  • < 18 years of age

Contacts and Locations

Locations

Site City State Country Postal Code
1 Mount Carmel Health System Columbus Ohio United States 43213

Sponsors and Collaborators

  • Mount Carmel Health System
  • Mount Carmel Foundation

Investigators

  • Study Chair: James Dombroski, MD, Mount Carmel Health System

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Mount Carmel Health System
ClinicalTrials.gov Identifier:
NCT04956094
Other Study ID Numbers:
  • 210412-1
First Posted:
Jul 9, 2021
Last Update Posted:
Jul 16, 2021
Last Verified:
Jun 1, 2021
Individual Participant Data (IPD) Sharing Statement:
No
Plan to Share IPD:
No
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Keywords provided by Mount Carmel Health System
Additional relevant MeSH terms:

Study Results

No Results Posted as of Jul 16, 2021